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Summary 
Decreased activity of ADAMTS13, the von Willebrand factor 
(VWF) cleaving protease, was recently reported in cardiovascu-
lar diseases and in hepatic failure. Chronic heart failure (CHF) is 
characterised by abnormalities of left ventricular function ac-
companied by the failure of the liver and dysregulation of en-
dothelial activation. Therefore, the aim of our study was to 
measure ADAMTS13 activity in CHF, and determine the prog-
nostic value of VWF and ADAMTS13 on major clinical events in 
CHF. 
ADAMTS13 activity (measured by FRETS-VWF73 substrate) 
was decreased in CHF (n = 152, left ventricular ejection fraction 
<45%), and it correlated negatively with B-type natriuretic pep-
tide (BNP) NYHA (New York Heart Association) classes, 
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markers of synthetic capacity of the liver and endothelial dys-
function (all p<0.005). Both, high VWF:Ag levels (hazard ratio 
[HR] 1.52, 95% confidence interval [CI] 1.189–1.943), and low 
ADAMTS13/VWF:Ag ratios (HR 0.70, 95% CI 0.58–0.84) inde-
pendently and significantly predicted short-term (1 year follow-
up) clinical adverse events in heart failure (HF). 
Decreased activity of ADAMTS13 with concomitant high 
VWF:Ag levels is a significant independent predictor of clinical 
events in CHF. The levels of the two molecules may integrate the 
impaired synthetic capacity of the liver and the disturbed en-
dothelial regulation and can therefore be a useful tool to predict 
clinical events in CHF. 
Thromb Haemost 2009; 102: 573–580 
Blood Coagulation, Fibrinolysis and Cellular Haemostasis 
Correspondence to: 
Zoltán Prohászka, MD, DSc 
IIIrd Department of Internal Medicine 
Semmelweis University 
H-1125 Budapest, Kútvölgyi út 4. 
Tel.: +36 13251379, Fax: +36 12253899,  
E-mail: prohoz@kut.sote.hu 
 
Received: January 15, 2009 
Accepted after major revision: June 13, 2009 
 
Prepublished online: July 30, 2009 
doi:10.1160/TH09-01-0036
Introduction 
The clinical syndrome of chronic heart failure (CHF) is char-
acterised by abnormalities of left ventricular function and neuro-
hormonal regulation, which are accompanied by effort intoler-
ance, fluid retention, decreased longevity and severe failure of 
most of the organs. Endothelial injury is a well known compli-
cation of CHF (1). It is demonstrated by impaired endothelium-
mediated vasodilation, but it also refers to a proinflammatory 
and prothrombotic state. The elevated level of von Willebrand 
factor (VWF) in CHF was described earlier (2, 3), and as ex-
pected, strong correlation was found between VWF and the 
markers of disease severity (4). Chong et al. (5) and Chin et al. 
(6) reported that high levels of VWF were associated with a 
worse outcome in CHF, although the size of the studies did not 
allow any detailed analysis. 
The VWF is released from endothelial cells in an ultra large 
form (ULVWF), which distinguishes itself not only by molecular 
weight but also by the ability to aggregate platelets in conditions 
of high shear stress (7, 8). The plasma metalloprotease 
ADAMTS13 (a disintegrin and metalloprotease with thrombos-
pondin type 1 motif, 13) cleaves prothrombotic ULVWF into less 
active multimers. Significantly reduced levels of ADAMTS13 
activity were found in physiological states, such as pregnancy 
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and the neonatal period, as well as several pathological con-
ditions, in spite of the absence of clinically overt thrombotic 
events (9). The measurement of ADAMTS13 activity has helped 
separate disease entities of thrombotic microangiopathies 
(TMA) on the base of molecular etiology (10). 
The gene for ADAMTS13 has been reported to be actively 
expressed in the liver stellate cells (11, 12) suggesting that the 
liver may be a source of plasma ADAMTS13. ADAMTS13 ac-
tivity was shown to be decreased in patients with severe hepatic 
disease (13–15). Furthermore, ADAMTS13 expression was re-
cently shown by unstimulated human platelets, and the ex-
pression increases upon thrombin stimulation (16). In addition, 
human endothelial cells have also been shown to express 
ADAMTS13 mRNA and constitutively synthesise and release 
the protein (17), while the ADAMTS13 expression of human 
renal podocytes and endothelium were also detected (18). 
Since CHF is a proper model disease to study disturbed en-
dothelial-, renal- and hepatic function together with the constant 
inflammation we hypothesised that ADAMTS13 activity and 
VWF antigen levels are altered in CHF. Here in this study we re-
port for the first time, that decreased ADAMTS13 activity is as-
sociated with increased severity of heart failure. Furthermore, 
the VWF level and the ratio of ADAMTS13/VWF:Ag has inde-
pendent predictive power for severe clinical events in CHF. In ad-
dition, data from our well-characterised CHF cohort allowed us 
to conclude that low ADAMTS13 activity is linked to impaired 
hepatic synthetic capacity and endothelial dysfunction in CHF.  
Methods 
Study cohort 
The study was carried out in accordance with the Helsinki Dec-
laration at the IIIrd Department of Internal Medicine, Semmel-
weis University, based on a study protocol approved by the high-
est Ethical Committee of Hungary. Consecutive patients with 
clinical signs of CHF referred to trans-thoracic echocardio-
graphy were considered for inclusion. All patients with <45% 
left ventricular ejection fraction who provided written informed 
consent were included independently of the etiology of the dis-
ease from the out- or inpatient cardiology departments. Patients 
with co-existing malignant or acute infectious conditions were 
not included. A total of 152 patients (112 men, 40 women) were 
enrolled between February 2005, and July 2006. The full clinical 
record of the patients was registered at inclusion with the de-
tailed physical status and routine laboratory tests. All patients 
were on optimised heart failure treatment, 58.6% took loop diu-
retics, 53.9% were on ACE-inhibitors and 52% took β-blockers. 
All patients were contacted after 1-year from study entrance. For 
patients alive one year after inclusion, all major clinical events 
(re-hospitalisation due to worsening of heart failure [HF], or lack 
of it) were registered. Information on mortality (with specific 
cause of death) was collected from hospital database, medical 
staff or family members.  
Blood samples were taken after 6 hours of fasting between 8 
and 10 am by antecubital veinpuncture into native, EDTA- and 
sodium citrate anticoagulated tubes. The samples were pro-
cessed to obtain aliquots of serum and plasma and later stored at 
–70 °C until further analysis. 
Determination of ADAMTS13 activity 
The fluorigenic substrate, FRETS-VWF73, was purchased from 
Peptides International (Louisville, KY, USA) and applied for the 
determination of ADAMTS13 enzyme activity according to the 
protocol provided by the supplier with minor modifications. 
Briefly, citrated plasma was diluted 1:20 in assay buffer (5 
mmol/l Bis-Tris, 25 mmol/CaCl2, 0.005% Tween 20, pH 6.0) 
and mixed with 5 µmol/l FRETS-VWF73 substrate solution (20 
µl each, in white 384-well plates. Fluorescence was measured at 
37oC every 2 minutes for 1 hour in Chameleon microplate reader 
(Hidex, Turku, Finland) equipped with a 340 nm excitation and a 
460 nm emission filter. The reaction rate was calculated by linear 
regression analysis of fluorescence over time. A two-fold dilu-
tion series of normal human plasma (mixed from citrated plasma 
samples of 10 healthy blood donors) was applied as standard 
curve, 100% ADAMTS13 activity was set at the reaction rate ob-
served in the 1:20 diluted sample. The intra-assay variation coef-
ficient was <5%, the inter-assay coefficient of variation (CV) % 
was 6–9% (measured at 60 and 100% activity levels). In some 
plasma samples, we also measured ADAMTS13 enzyme activity 
with the collagen-binding assay, as described by Gerritsen et al. 
(19). The results of the FRETS-VWF73 assay showed good 
agreement with that of the collagen-binding method (20). 
Determination of immunoreactive von Willebrand fac-
tor levels (VWF:Ag) 
VWF:Ag was measured by ELISA according to Cejka (21), 
using primary and HRP (horseradish peroxidase) labelled sec-
ondary polyclonal rabbit anti-human VWF antibodies (DakoCy-
tomation, Glostrup, Denmark) and TMB (tetramethylbenzidine) 
substrate. Three dilutions of the samples were applied into the 
ELISA wells. Washing buffer (0.01M PBS with 0.1% Tween 20, 
pH 7.4) was used for the dilution. Optical density reading was 
carried out using Infiniti 200M (Tecan Trading AG, Switzer-
land), and the Magellan software of the instrument was used for 
calculations, applying Four Parameter Marquardt curve fitting. 
WHO VWF:Ag Standard was used for calibration and the results 
of different plasma dilutions (after multiplying) were averaged 
only if the OD values were in the measurement range (typically 
between 0.064–1.673). Intra- and inter assay CVs were 7.1 % 
and 10.6% for Dade Behring normal control plasma (when the 
values of the two dilutions were evaluated individually). 
Determination of other laboratory parameters 
Levels of NT-proBNP (Biomedica ELISA kit (Cat No. 
BI-20852)), serum TNF-alpha (R&D System high sensitivity 
ELISA kit (Cat No. HSTA00C)), and serum IL-6 (R&D System 
high sensitivity ELISA kit (Cat No.HS600B)) were measured 
according to the manufacturer's instructions. Plasma CT-
proET-1 (C-terminal-pro-endothelin-1) levels, referring to ET-1 
were measured by a novel sandwich immunoluminometric assay 
using 2 polyclonal antibodies (BRAHMS AG, Hennigsdorf, 
Germany), as previously described (22). Standard laboratory pa-
rameters were measured by Roche Integra 800 (clinical chemis-
try, CRP), or by Cell-Dyn 3500 hematology analyser (complete 
blood count). 
Statistical analysis, power calculations 
For descriptive purposes the values of each measurement are 
given as median and 25th-75th percentile, or as numbers (per-
cent), since most of the variables were not normally distributed, 
except ADAMTS13 activity. Non-parametric tests were used for 
group comparisons; continuous variables between two groups 
were compared with Mann-Whitney U test, whereas categorical 
variables were compared with Pearson’s χ2 test. Spearman rank 
order correlation coefficients were calculated for estimation of 
interrelations between ADAMTS13 activity, VWF:Ag and other 
variables. The association between NYHA classes and plasma 
activity of ADAMTS13, and VWF:Ag level were calculated 
using Kruskal-Wallis ANOVA by ranks test. 
Multivariate Cox proportional hazard models were fitted to 
assess the effect of ADAMTS13 activity/ VWF:Ag, and 
VWF:Ag on CHF event free survival. Survival times were 
measured from inclusion in the study until both of the endpoints 
studied, all-cause mortality or rehospitalisation due to CHF. The 
studied patient characteristics and laboratory markers together 
with the logarithm transformed variants of the continuous vari-
ables were pre-evaluated using a multitude of univariate Cox re-
gressions. The best predictors by their chi-square values of like-
lihood ratio tests were noted and the plain or logarithmic variants 
of the predictors were selected for later inclusion in the multi-
variate models. One predictor was included in the multivariate 
models from each group of variables of clinically justified path-
ological pathways to adjust for the known effects and the studied 
variables. The results of the Cox regression models are presented 
as hazard ratios standardised on 1 SD (standard deviation) range 
of the predictors (if not otherwise stated), the corresponding 
(n) All patients (152) With event* (63) 
Male (%) 112 (73.7%)  44 (69.8) 
Age (years)  67 (58.6–76.6)  68.8 (59–76) 
NYHA (n, I/II/III/IV)  30/51/53/18   4/19/27/13 
NT-proBNP (pmol/ml)   0.86 (0.41–1.92)   1.2 (0.57–0.32) 
CT-proET-1 (pmol/l) 
LV-EF (%) 
Peripheral oedema (%) 
Heart rate (1/min) 
Diastolic BP (Hgmm) 
BMI (kg/m2) 
Se. sodium (mmol/l) 
Se. creatinine (μmol/l) 
Se. bilirubin (μmol/l) 
AST (U/l) 
ALT (U/l) 
ALP (U/l) 
Gamma-GT (U/l) 
HGB (g/l) 
PLT (109/l) 
CRP (mg/l) 
Albumin (g/l) 
Total protein (g/l) 
IL-6 (pg/ml) 
TNF-alpha (pg/ml) 
ADAMTS13 act. (%) 
VWF:Ag(%) 
ADAMTS13/VWF  
106 (73–152) 
 34 (27–40) 
 64 (42.1%) 
 80 (70–94) 
 80 (70–95) 
 26.4 (24.4–30.9) 
140 (138–143) 
 97 (78–119) 
 13.4 (9.0–19.6) 
 23 (18–33) 
 24 (18–36) 
 80.5 (66–105.6) 
 70.4 (34–126) 
141 (131–152) 
190 (161–231) 
  6.1 (2.8–15.3) 
 41 (38–44) 
 71.1 (7.7) 
  9.9 (5.5–16.3) 
  2.5 (1.6–4.1) 
 76.7 (27.7) 
182.0 (142.5–277.0) 
  0.38 (0.25–0.60) 
143 (85.6–186) 
 30 (23–38) 
 34 (54.0) 
 80 (70–96) 
 75 (60–80) 
 26.6 (24.0–32.0) 
139 (135–142) 
108 (87–165) 
 14.6 (9.9–21) 
 23 (19–32) 
 25.5 (17–38) 
 88 (69–120) 
 79 (37–143) 
138 (123–152) 
198.5 (168–233) 
  8.01 (2.9–20.8) 
 40 (38–44) 
 72 (67–77) 
 11.4 (8.34–15.53) 
  3.01 (1.96–5.18) 
 70.6 (48.4–94.9) 
215.0 (156.0–330.0) 
  0.29 (0.20–0.43) 
Event-free (89) 
 68 (76.4) 
 69.17 (58.2–77.2) 
 26/33/25/5 
  0.63 (0.36–1.40) 
 92.6 (65.7–126) 
 35 (29–41) 
 30 (33.7) 
 80 (65.5–92) 
 80 (70–80) 
 26.3 (24.4–30.6) 
141 (139–143) 
 91 (74–112) 
 12.12 (8.9–19.2) 
 24 (18–34) 
 23 (18–36) 
 78 (65–103) 
 62 (28–102) 
143 (132–154) 
187 (159–216) 
  5.11 (2.67–12.15) 
 41 (38–44) 
 71.5 (66.5–76.5) 
  8.16 (4.18–16.23) 
  2.2 (1.41–3.62) 
 79.2 (61.4–95.2) 
165.0 (128.0–226.0) 
  0.45 (0.34–0.66) 
p-value** 
 0.365 
 0.978 
 0.0002 
 0.001 
<0.0001 
 0.003 
 0.013 
 0.333 
 0.099 
 0.956 
 0.001 
 0.001 
 0.202 
 0.768 
 0.959 
 0.156 
 0.076 
 0.128 
 0.296 
 0.074 
 0.256 
 0.728 
 0.008 
 0.023 
 0.049 
 0.002 
<0.0001 
Numbers in the table represent median (interquartile range) or numbers of patients (percentage). *Event represents all cause mortality or re-hospitalisation 
due to the progression of the HF, during the first year of follow up. **Mann-Whitney test or Perason Chi-square test. 
NYHA – New York Heart Association, NT-proBNP – N-terminal pro-Brain-Natriuretic-Peptide, CT-proET-1 – C-Terminal pro-Endothelin-1, LV-EF – Left Ven-
tricular Ejection Fraction, BP – Blood Pressure, BMI – Body Mass Index, AST – Aspartate Aminotransferase, ALT – Alanine Transaminase, ALP – Alkaline Phos-
phatase, Gamma-GT – Gamma Glutamyl Transpeptidase, HGB – Haemoglobin, PLT – Platelets, CRP – C-Reactive Protein, IL-6 – Interleukin-6, TNF – Tumor 
Necrosis Factor, ADAMTS13 – A Disintegrin And Metalloprotease with Thrombospondin type 1 motif 13, VWF – von Willebrand Factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Basic clinical char-
acteristic of the study co-
hort. 
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95% confidence intervals (CI) and the chi-square and p-values 
of likelihood ratio tests. Age was considered as a time-dependent 
covariate. 
The power of our study to detect the observed differences in 
ADAMTS13/VWF ratio between the ’event-free’ and the ’with 
event’ patient group, at a Type I Error rate of 0.05, was 95.5%. 
Statistical analyses were carried out using the software 
STATISTICA 7.0 (StatSoft Inc., Tulsa, OK, USA), GraphPad 
Prism 4.03 (GraphPad Software, San Diego, CA, USA) and 
SPSS 13.01 (Apache Software Foundation, USA). Two tailed 
p-values were calculated and the significance level was put at a 
value of p<0.05. 
Results 
Characteristics of the patient cohort 
The basic clinical characteristics of the patient cohort are given 
in Table 1. The aetiology of heart failure was ischaemic/non-is-
chaemic in 60/40% of the patients. All of the patients had mani-
fest left ventricular systolic dysfunction (LVEF <45%), however, 
disease severity spanned from NYHA class I to IV, and NT-
proBNP levels from 0.129 to 11.298 pmol/ml. There were 47 
outpatients (31%) and 105 (69%) in-hospital patients. Thus, our 
cohort included patients with mild, moderate and severe HF. The 
cohort was extensively characterised in order to get detailed in-
formation for heart function, salt- and water-homeostasis, he-
patic-, renal-, haemopoetic- and endothelial dysfunction, in-
flammation (Table 1). The mean ADAMTS13 activity was 
76.7% (SD 27.7) in the CHF cohort showing normal distribution 
(Shapiro-Wilks test for normality p=0.72). One patient, who had 
large anterior acute myocardial infarction 5 years before enrol-
ment into the study, had 1% ADAMTS13 activity with blocking 
anti-ADAMTS13 antibodies (measured repeatedly in consecu-
tive samples taken >3 years apart) without any history of TTP 
(thrombotic thrombocytopenic purpura) or low platelet counts. 
Severely decreased (<10%) ADAMTS13 activity levels were not 
observed in other cases. Low ADAMTS13 activity levels were 
not associated with decreased platelet counts in the CHF cohort. 
The clinical and laboratory parameters of patients with or 
without clinical events (all-cause mortality or re-hospitalisation) 
during the first 365 days of follow up are given in Table 1. Event 
free survival, among other variables, was associated with moder-
ate disease and lower NT-proBNP levels, significantly higher 
ADAMTS13 activity, decreased VWF:Ag level and higher 
ADAMTS13/VWF ratio. 
Association of decreased ADAMTS13 activity and in-
creased VWF:Ag levels with disease severity in heart 
failure 
As presented in Figure 1 low ADAMTS13 activity (p = 0.009) 
and high VWF:Ag levels (p = 0.0001) were associated with in-
creasing NYHA functional class with the lowest ADAMTS13 
activity levels in NYHA class IV. Accordingly, the ratio of 
ADAMTS13/VWF:Ag decreased across NYHA classes reach-
ing a median as low as 0.21 in NYHA IV in contrast to 0.58 in 
NYHA I. Confirming the association of ADAMTS13 activity 
and VWF:Ag concentrations with severity of heart failure is the 
observation presented in panels B and C in Figure 1., showing 
the highly significant correlations of ADAMTS13 activity and 
VWF:Ag with NT-proBNP levels. 
Prediction of clinical events by high VWF:Ag levels and 
low ADAMTS13/VWF ratio 
In univariate models low ADAMTS13 activity, high VWF:Ag 
levels and their ratio were all significant predictors of clinical 
events (data not shown). In the multivariable Cox models after 
adjustments for key clinical covariates (age, BMI, serum sodium 
levels, diastolic blood pressure, heart rate, haemoglobin and cre-
Figure 1: Panel A: Association of ADAMTS13 activity (■) and von-Willebrand factor antigen levels (▲) with severity of chronic 
heart failure (mean, 95% confidence interval, both on left Y-axis, n = 152). Results of Kruskal-Wallis ANOVA: ADAMTS13 F = 3.98, p = 
0.009; VWF:Ag F = 6.89, p = 0.0001. The ADAMTS13 activity/VWF:Ag ratio is indicated by solid line (right Y-axis). Panel B and C: Correlation be-
tween NT-proBNP levels and ADAMTS13 activity (r = -0.41, p<0.0001) or von Willebrand factor antigen concentrations (r = 0.21, p = 0.010). 
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atinine level), the standardised hazard ratio for VWF:Ag was 
1.52 (CI: 1.189–1.943), and for ADAMTS13/VWF:Ag 0.70 (CI: 
0.579–0.845) (Table 2). The chi-square value of 
ADAMTS13/VWF:Ag (15.742) is twice, and thus markedly 
higher than that of VWF:Ag (10.194), indicating that the ratio 
has substantially higher predictive power as compared to the 
VWF antigen levels. ADAMTS13 activity levels were not sig-
nificant predictors of clinical events in the adjusted models, indi-
cating that its primary association with disease severity is de-
pendent on important clinical variables and may be a result of co-
variance. Therefore, utilising our well-characterised CHF cohort 
we searched for laboratory and clinical correlates of 
ADAMTS13 activity levels. 
Correlations of ADAMTS13 activity, VWF:Ag levels and 
their ratio with the laboratory and clinical parameters 
Table 3 shows the Spearman rank correlation coefficients of 
ADAMTS13 activity, VWF:Ag levels and their ratio with the 
clinical and laboratory parameters. Both studied factors cor-
related significantly with the parameters of disease severity, like 
NYHA classes, NT-proBNP, and the presence of peripheral 
oedema. Significant (even after multiplying the p-values accord-
ing to Bonferroni’s rule) correlation was found between 
ADAMTS13 and the synthetic function of the liver (albumin, 
total protein) and a marker of endothelial dysfunction (CT-
proET-1), but ADAMTS13 activity did not show significant cor-
relation with inflammatory markers and liver enzymes. VWF:Ag 
correlated strongly with the signs of renal function and inflam-
mation (acute phase reaction and IL-6). The ratio of 
ADAMTS13/VWF:Ag showed highly significant correlations 
with the same biomarkers of the above mentioned pathways as 
ADAMTS13 activity. 
HR 95% CI 
VWF 1.520 1.189–1.943 
Creatinine 1.177 0.9171.511 
Heart rate 1.008 0.995–1.021 
BMI 1.044 0.830–1.314 
Diastolic BP 
Sodium 
Haemoglobin 
Age (year) 
ADAMTS13/VWF 
Creatinine 
Heart rate 
BMI 
Diastolic BP 
Sodium 
Haemoglobin 
Age (year) 
0.798 
0.867 
0.761 
1.002 
HR 
0.700 
1.219 
1.010 
1.108 
0.847 
0.870 
0.786 
1.002 
0.621–1.026 
0.639–1.169 
0.606–0.956 
0.999–1.005 
95% CI 
0.579–0.845 
0.946–1.571 
0.997–1.024 
0.883–1.390 
0.657–1.093 
0.650–1.163 
0.630–0.981 
0.999–1.005 
Chi-square 
10.194 
 1.582 
 1.377 
 0.134 
 3.167 
 0.876 
  5.185 
 1.642 
Chi-square 
15.742 
 2.229 
 2.118 
 0.764 
 1.654 
 0.865 
 4.275 
 2.025 
p-value 
0.001 
0.208 
0.241 
0.714 
0.075 
0.349 
0.023 
0.440 
p-value 
<0.0001 
0.135 
0.146 
0.382 
0.198 
0.352 
0.039 
0.363 
A     
B     
Hazard ratios /1SD increase or decrease (if not otherwise stated) with their 95% CI, chi-squares 
and p-values of likelihood tests are presented. 
VWF – von Willebrand Factor, BMI – Body Mass Index, BP – Blood Pressure, ADAMTS13 – A Dis-
integrin And Metalloprotease with Thrombospondin type 1 motif 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Final multivariable models of high VWF:Ag levels (A) 
and low ADAMTS13/VWF:Ag ratios (B) for prediction of clini-
cal events (all-cause mortality or re-hospitalisation due to wor-
sening of HF) in patients with chronic heart failure. 
 ADAMTS13 
r p-value 
Age  –0.27  0.0009 
NYHA –0.23  0.005 
NT-proBNP –0.44 <0.0001 
CT-proET-1 
BMI 
Se. sodium 
Se. creatinine 
Se. bilirubin 
Albumin 
HGB 
PLT 
CRP 
Total protein 
ADAMTS13 
–0.29 
 0.25 
 0.003 
–0.18 
–0.20 
 0.25 
 0.14 
 0.06 
–0.14 
 0.28 
 
 0.0003 
 0.002 
 0.97 
 0.023 
 0.013 
 0.003 
 0.09 
 0.30 
 0.09 
<0.001 
 
VWF:Ag 
r 
 0.16 
 0.33 
 0.21 
 0.31 
 0.08 
–0.30 
 0.26 
 0.03 
–0.34 
–0.02 
–0.03 
 0.37 
–0.07 
–0.17 
p-value 
 0.043 
<0.0001 
 0.010 
<0.0001 
 0.29 
 0.0002 
 0.001 
 0.71 
<0.0001 
 0.79 
 0.72 
<0.0001 
 0.384 
 0.042 
ADAMTS13/VWF 
r 
–0.28 
–0.34 
–0.41 
–0.44 
 0.04 
 0.22 
–0.28 
–0.15 
 0.36 
 0.07 
 0.06 
–0.31 
 0.19 
- 
p-value 
 0.0003 
<0.0001 
<0.0001 
<0.0001 
 0.649 
 0.006 
 0.0003 
 0.074 
<0.0001 
 0.39 
 0.46 
<0.0001 
 0.018 
- 
Spearman rank correlation coefficients with p-values are presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Correlation be-
tween ADAMTS13 activity, 
von Willebrand antigen 
levels, and their ratio and 
clinical variables in pa-
tients with chronic heart 
failure (n=152). 
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Discussion 
The novel observation reported in this study is, that ADAMTS13 
activity is decreased in chronic heart failure. Low ADAMTS13 
activities are accompanied with high VWF:Ag levels and their 
ratio gradually decrease with worsening HF. Furthermore, both, 
high VWF:Ag levels and low ADAMTS13/VWF:Ag ratios inde-
pendently and highly significantly predict short-term clinical ad-
verse events in HF. ADAMTS13 activity alone is non-significant 
predictor of clinical events in the adjusted models (data not 
shown). Levels of ADAMTS13 activity correlates with impor-
tant clinical variables including markers of synthetic capacity of 
the liver and endothelial dysfunction. 
Multiple mechanisms accounting for the moderately de-
creased ADAMTS13 activities may dominate in CHF. First, the 
impaired hepatic synthetic capacity may be linked to decreased 
production of the protease, since the liver is one of the sources of 
ADAMTS13 (11, 12). Undernutrition is one of the hallmark 
characteristics accompanying the progression of heart failure 
(23), which can lead to hypoproteinamia as well. Second, since 
endothelial cells are also major sources of ADAMTS13 (17), the 
chronic endothelial activation may also be one reason for de-
creased activity. Supporting this assumption is our observation 
on the strong inverse correlation between endothelin-1 and 
ADAMTS13 levels. Third, increased consumption may also lead 
to decreased activity of ADAMTS13, since the endothelial dys-
function in CHF results in elevated secretion of immature 
VWF:Ag (2, 3), and it was reported that secondary consumption 
of ADAMTS13 may occur (24). 
Several potential mechanisms, suggested by literature data 
(25–28), were also considered as potential co-variates of 
ADAMTS13 activities in our study. Inhibition of ADAMTS13 
by the inflammatory cytokine IL-6 was shown in in vitro studies 
(25). Stimulated by these findings we investigated whether IL-6 
and TNF-alpha plasma levels are related to ADAMTS13, but no 
significant correlations were observed. The role of inflammation 
in the regulation of ADAMTS13 activity was further investi-
gated by its relation to acute phase reactants (26). The same was 
the case when analysing the relationship with serum creatinine 
levels and age: neither showed independent association with 
ADAMTS13 activity in multiple regression models (data not 
shown). Furthermore, none of our patients suffered from dis-
seminated intravascular coagulation (DIC) as evidence by the 
lack of decreased fibrinogen levels (data not shown). Therefore, 
the inactivation of ADAMTS13 by thrombin or plasmin (as pres-
ented in patients with sepsis induced DIC [28]) in CHF is most 
probably not present. 
In complete agreement with Chin et al. (6) we report here a 
significant prediction of clinical events in CHF by increased 
VWF:Ag levels. Increased VWF antigen levels are related to en-
dothelial damage, an important contributing factor to progres-
sion of HF. However, the ratio of ADAMTS13/VWF:Ag seems 
to have much higher predictive power as compared to that of 
VWF antigen levels alone in the standardised hazard models 
(Table 2). Since ADAMTS13 activity is strongly related to hypo-
proteinemia and endothelial damage, it is tempting to speculate 
that the ratio represents multiple pathophysiological pathways in 
CHF in an integrated manner. 
A large body of evidence supports an important prognostic 
value of decreased ADAMTS13 activity in cardiovascular dis-
eases. Bongers et al. (29) reported increased risk of ischaemic 
stroke in patients with low ADAMTS13 levels. In patients after 
myocardial infarction, Cox hazard analysis revealed that the 
early increase of VWF levels and VWF/ADAMTS13 ratio, and 
the early decrease of ADAMTS13 levels were significant predic-
tors of future thrombotic events during the 1-year follow up peri-
od (30). The same group also reported significantly lower 
ADAMTS13 antigen levels in patients with unstable angina 
compared to stable angina and chest pain syndrome (30). Craw-
ley et al. (31) and Chion at al. (32) also reported an association of 
ADAMTS13 with the risk of myocardial infarction. In line with 
these observations are our results presented in this study on the 
significant prediction of clinical events by ADAMTS13/VWF:Ag 
ratio. Since this ratio correlated with multiple important labora-
tory and clinical variables measured and registered in our study, it 
is tempting to speculate that it may represent increased risk in an 
integrated manner. Supporting this hypothesis is that according to 
the results of the adjusted Cox models the ADAMTS13/VWF:Ag 
ratio is independent predictor of clinical events. 
Our results on the increased levels of VWF:Ag together with 
decreased ADAMTS13 due to the high thrombotic risk may ex-
plain that patients with CHF have an increased rate of venous 
thromboembolism and stroke, as well as recurrent ischaemia and 
infarction (33). The causes of death in CHF are largely cardiac in 
origin, and usually result from lethal arrhythmias, but both epi-
demiological and autopsy results suggest that acute intra-coron-
ary thrombotic occlusion may be the probable triggering event 
(34, 35). CHF patients can therefore be regarded to be at high risk 
of thrombosis-related complications. Indeed, the components of 
Virchow’s triad are fulfilled in CHF, with abnormalities of flow 
(poor cardiac function), vessel wall (endothelial dysfunction/
damage) and blood constituents, with significant abnormalities 
of haemostatic factors and platelet function (36, 37). 
It should be noted that the level of decrease in ADAMTS13 
activity did not reach those regarded as severely decreased activ-
ity (<10%), and indeed, it was not related with decreased platelet 
numbers (Table 3). Rather, the decrease of ADAMTS13 activity 
was mild, and seemingly regulated by and connected to mechan-
isms related to disease severity, hepatic function and inflam-
mation. 
What is known about this topic? 
− Chronic heart failure is characterised by constant  
endothelial dysregulation. 
– vWF:Ag levels are elevated in CHF and predict clinical 
events. 
What does this paper add? 
− Decreased activity of ADAMTS13 with concomitant high 
vWF:Ag levels is a significant independent predictor of 
clinical events in CHF. 
 – Low ADAMTS13 activity is related to decreased hepatic 
synthetic capacity and endothelial dysfunction.
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A potential limitation of our study is the application of the 
FRETS-VWF73 rapid fluorigenic assay for the measurement of 
ADAMTS13 activity. This assay is not the most widely used 
assay in studies on ADAMTS13 activity. However, according to 
literature data (38) and our observations (39), both, the widely 
used assays by detecting VWF multimeric structure by its ligand-
binding activities and the FRETS-VWF73 assay exhibit reliable 
results to detect low, moderately reduced as well as normal level 
of ADAMTS13 activity. 
To obtain more information on the role of ADAMTS13 in 
cardiovascular diseases, and particularly on increased throm-
botic risk, is not only a mechanistic interest, because prepara-
tions of recombinant ADAMTS13 might have a potential appli-
cation in the control of this risk (24, 40). Further prospective 
studies are needed to provide more causative results on the prog-
nostic role of the VWF-ADAMTS13 pathway in these diseases 
before such supplementary therapies may be indicated. 
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